• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer With Brain Metastasis: Can Up-Front Radiation Therapy Be Deferred or Withheld?

作者信息

Zhou Lin, Deng Lei, Lu You

机构信息

Lin Zhou, Lei Deng, and You Lu, West China Hospital, Sichuan University, Chengdu, China.

出版信息

J Clin Oncol. 2017 Apr 1;35(10):1033-1035. doi: 10.1200/JCO.2016.71.5706. Epub 2017 Jan 23.

DOI:10.1200/JCO.2016.71.5706
PMID:28113018
Abstract
摘要

相似文献

1
Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer With Brain Metastasis: Can Up-Front Radiation Therapy Be Deferred or Withheld?非小细胞肺癌脑转移患者的表皮生长因子受体突变：能否推迟或不进行 upfront 放疗？
J Clin Oncol. 2017 Apr 1;35(10):1033-1035. doi: 10.1200/JCO.2016.71.5706. Epub 2017 Jan 23.
2
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.非小细胞肺癌患者的表皮生长因子受体突变与脑转移模式
Korean J Intern Med. 2018 Jan;33(1):168-175. doi: 10.3904/kjim.2015.158. Epub 2016 Apr 20.
3
Comment on "Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery", by Yang WC et al.对Yang WC等人所著的《表皮生长因子受体突变预测接受立体定向放射外科治疗的非小细胞肺癌脑转移患者的良好预后》的评论
Radiother Oncol. 2018 Oct;129(1):187. doi: 10.1016/j.radonc.2017.12.003. Epub 2017 Dec 15.
4
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.upfront颅部放射治疗后使用厄洛替尼对伴有脑转移的表皮生长因子受体突变型非小细胞肺癌的临床结局有积极影响。
Anticancer Res. 2019 Feb;39(2):923-931. doi: 10.21873/anticanres.13195.
5
Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.比较第一代表皮生长因子受体酪氨酸激酶抑制剂治疗携带 EGFR 突变的晚期非小细胞肺癌脑转移患者的疗效。
BMC Cancer. 2018 Oct 22;18(1):1012. doi: 10.1186/s12885-018-4911-7.
6
Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.表皮生长因子受体激活突变在肺腺癌伴脑转移患者中的附加预后作用：与肺特异性 GPA 评分相结合。
Lung Cancer. 2014 Dec;86(3):363-8. doi: 10.1016/j.lungcan.2014.10.001. Epub 2014 Oct 13.
7
Clinical Analysis of Uncommon Epidermal Growth Factor Receptor Mutations in 16 Cases of Nonsmall Cell Lung Cancer.16例非小细胞肺癌中罕见表皮生长因子受体突变的临床分析
Chin Med J (Engl). 2018 Apr 20;131(8):1005-1006. doi: 10.4103/0366-6999.229887.
8
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌患者一线吉非替尼治疗后化疗的疗效——一项比较吉非替尼与卡铂加紫杉醇的随机III期研究（NEJ002）的数据
Jpn J Clin Oncol. 2015 Jul;45(7):670-6. doi: 10.1093/jjco/hyv054. Epub 2015 Apr 15.
9
Post-recurrence survival analysis of stage I non-small-cell lung cancer.I期非小细胞肺癌复发后的生存分析
Asian Cardiovasc Thorac Ann. 2017 Nov;25(9):623-629. doi: 10.1177/0218492317737641. Epub 2017 Oct 23.
10
Early stage non-small cell lung cancer patients need brain imaging regardless of symptoms.早期非小细胞肺癌患者无论有无症状均需进行脑部成像。
Int J Clin Oncol. 2018 Aug;23(4):641-646. doi: 10.1007/s10147-018-1254-y. Epub 2018 Feb 26.

引用本文的文献

1
Comprehensive Analysis of Lung Cancer Metastasis: Sites, Rates, Survival, and Risk Factors-A Systematic Review and Meta-Analysis.肺癌转移的综合分析：部位、发生率、生存率及危险因素——一项系统评价与荟萃分析
Clin Respir J. 2025 Jul;19(7):e70107. doi: 10.1111/crj.70107.
2
Therapeutic Outcomes of Osimertinib in EGFR - Mutant Non-Small Cell Lung Cancer With Brain Metastases: Results From a Retrospective Study at Vietnam National Cancer Hospital.奥希替尼治疗伴有脑转移的EGFR突变型非小细胞肺癌的疗效：越南国家癌症医院的一项回顾性研究结果
Cancer Control. 2025 Jan-Dec;32:10732748251348429. doi: 10.1177/10732748251348429. Epub 2025 Jun 12.
3
Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists.
表皮生长因子受体突变阳性的非小细胞肺癌脑转移患者的治疗偏好：中国肿瘤学家的大规模调查
Ann Transl Med. 2022 Jan;10(2):41. doi: 10.21037/atm-21-6413.
4
Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases.脑转移中复发性 PTPRZ1-MET 融合和 MET 外显子 14 跳跃的高发生率。
Cancer Sci. 2022 Feb;113(2):796-801. doi: 10.1111/cas.15211. Epub 2021 Nov 30.
5
Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.肺腺癌伴 EGFR 敏感突变和同步脑转移患者一线 EGFR-TKI 治疗中脑放疗的价值和意义：合适的时机和技术。
Thorac Cancer. 2021 Dec;12(23):3157-3168. doi: 10.1111/1759-7714.14169. Epub 2021 Oct 14.
6
Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.脑转移 NSCLC 患者全脑放疗联合或不联合厄洛替尼治疗的多中心、开放标签、随机、对照 III 期试验。
Neuro Oncol. 2021 Jun 1;23(6):967-978. doi: 10.1093/neuonc/noaa281.
7
The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases.表皮生长因子受体（EGFR）突变状态及单发脑转移对非小细胞肺癌脑转移患者生存的影响
Neurooncol Adv. 2020 May 28;2(1):vdaa064. doi: 10.1093/noajnl/vdaa064. eCollection 2020 Jan-Dec.
8
Complete Remission of Multiple Brain Metastases in a Patient with -Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy.一名携带 - 突变的非小细胞肺癌患者在一线使用奥希替尼治疗且未接受放疗的情况下多发脑转移完全缓解。
Case Rep Oncol Med. 2020 Mar 19;2020:9076168. doi: 10.1155/2020/9076168. eCollection 2020.
9
Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases.表皮生长因子受体（EGFR）突变的非小细胞肺癌脑转移患者总生存预后因素的真实世界数据
J Cancer. 2019 Jun 9;10(15):3486-3493. doi: 10.7150/jca.30292. eCollection 2019.
10
Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.upfront颅部放射治疗与单纯表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌脑转移：1465例患者的Meta分析
Front Oncol. 2018 Dec 12;8:603. doi: 10.3389/fonc.2018.00603. eCollection 2018.